SCHEMBL3011774

SCHEMBL3011774

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
CPT1A P50416 7/20 0.37
CPT1B Q92523 6/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.36
P2RX3 P56373 1/20 0.36
HTT P42858 1/20 0.36
CACNA1G O43497 1/20 0.35
CACNA1H O95180 1/20 0.35
CACNA1I Q9P0X4 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
CPT2 P23786 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016294 0.95 MAPT (0.39) MAPTTP53LMNATSHRCPT1A
SCHEMBL3011794 0.94 MAPT (0.39) MAPTTP53LMNATSHRCPT1A
SCHEMBL3019226 0.92 TP53 (0.39) MAPTTP53LMNATSHRCPT1A
SCHEMBL3018474 0.92 MAPT (0.40) MAPTTP53LMNATSHRCPT1A
SCHEMBL3015545 0.92 ALDH1A1 (0.41) MAPTLMNATSHRALDH1A1POLB
SCHEMBL3009617 0.91 GAA (0.36) MAPTTP53LMNATSHRALDH1A1
SCHEMBL3010381 0.91 TP53 (0.40) MAPTTP53LMNATSHRCPT1A
SCHEMBL15671702 0.91 MAPT (0.42) MAPTTP53LMNATSHRCPT1A
SCHEMBL3006331 0.91 TP53 (0.40) MAPTTP53LMNATSHRCPT1A
SCHEMBL3016811 0.90 MAPK1 (0.38) MAPTTP53LMNATSHRCPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885TP53 2880/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.